Roivant Sciences (ROIV) Cash from Investing Activities (2020 - 2025)

Roivant Sciences (ROIV) posted Cash from Investing Activities of -$855.8 million for Q4 2025, down 810.69% on a QoQ basis from $120.4 million in Q3 2025, and up 69.87% year-over-year from -$503.8 million in Q4 2024.

Roivant Sciences (ROIV) Cash from Investing Activities (2020 - 2025) Analysis & Trends

Roivant Sciences' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$855.8 million for Q4 2025.

  • Quarterly Cash from Investing Activities rose 69.87% year-over-year to -$855.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.7 billion (down 396.79% YoY) and the FY2026 annual result came in at -$682.3 million, up 61.37% from the prior year.
  • Cash from Investing Activities was -$855.8 million for Q4 2025 at Roivant Sciences, down from $120.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $5.2 billion in Q4 2023 and bottomed at -$3.3 billion in Q3 2024.
  • A 5-year average of -$165.6 million and a median of -$7.5 million in 2022 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 3392.76% — and 2025, when it slumped 112409.43%.
  • Roivant Sciences' Cash from Investing Activities stood at $309.0 million in 2021, then tumbled by 151.08% to -$157.8 million in 2022, then surged by 3392.76% to $5.2 billion in 2023, then slumped by 154.66% to -$2.8 billion in 2024, then surged by 69.87% to -$855.8 million in 2025.
  • Business Quant data shows ROIV's Cash from Investing Activities at -$855.8 million in Q4 2025, $120.4 million in Q3 2025, and -$1.1 billion in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn - -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.62 Bn 466.83 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.75 Bn 50.57 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn -25.54 Mn
10 Roivant Sciences 24.03 Bn 24.03 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -855.82 Mn
Dec 31, 2025 -855.82 Mn
Sep 30, 2025 120.42 Mn
Sep 30, 2025 120.42 Mn
Jun 30, 2025 -1.09 Bn
Jun 30, 2025 -1.09 Bn
Dec 31, 2024 -2.84 Bn
Dec 31, 2024 -2.84 Bn
Sep 30, 2024 -3.29 Bn
Sep 30, 2024 -3.29 Bn
Jun 30, 2024 -965,000.00
Jun 30, 2024 -965,000.00
Dec 31, 2023 5.20 Bn
Dec 31, 2023 5.20 Bn
Sep 30, 2023 -36.45 Mn
Sep 30, 2023 -36.45 Mn
Jun 30, 2023 105,000.00
Jun 30, 2023 105,000.00
Dec 31, 2022 -157.82 Mn
Dec 31, 2022 -157.82 Mn